Scientific-organizational aspects for developing an inventory of the donors of umbilical cord blood with CCR5 delta32/delta32 genotype for HIV infection treatment

Home/2014, Vol. 2, No. 1/Scientific-organizational aspects for developing an inventory of the donors of umbilical cord blood with CCR5 delta32/delta32 genotype for HIV infection treatment

Cell and Organ Transplantology. 2014; 2(1):39-43.
DOI: 10.22494/COT.V2I1.37

Scientific-organizational aspects for developing an inventory of the donors of umbilical cord blood with CCR5 delta32/delta32 genotype for HIV infection treatment

Pirozhkov I. A.1, 2, Smolyaninov A. B.1, 2, Chechetkin A. V.3, Ivolgin D. A.1,2
1Pokrovsky stem cell bank, St. Petersburg, Russian Federation
2Research laboratory of cell technologies of the Northwest State Medical University I.I. Mechnikov, St. Petersburg, Russian Federation
3Russian Federal State Research Institute of Hematology and Transfusiology of Federal Medical-Biological Agency, St. Petersburg, Russian Federation

Projections of the using umbilical cord blood for HIV infection cure consist in the transplantation of umbilical cord blood hematopoietic stem cells from the donors of homozygous CCR5 delta32 mutation carriers.
This work presents the results of screening evaluation of umbilical cord blood samples from the donors, included in the public registry of the Pokrovsky stem cells bank, for identification of the homozygous CCR5 delta32 polymorphism carriers and their following HLA typing to see the perspectives for creating a public registry of CCR5 delta32/ CCR5 delta32 donors of the umbilical cord blood for treatment of HIV-infected patients. Total 2860 umbilical cord blood samples were examined from which 29 samples with CCR5 delta32 / CCR5 delta32 genotype were selected.
High frequency of the HLA alleles most prevalent in the North-West region of the Russian Federation has been found in the donors of umbilical cord blood with wild CCR5 gene and among CCR5 delta32/delta32 donors.

Keywords: umbilical cord blood, HIV, CCR5 delta32, hematopoietic stem cells transplantation

Full Text PDF

1. Samson M, Labbe O, Mollereau C, et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996; 35(11):3362-3367.
2. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996; 382:722-725.
3. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996; 86(3):367-377.
4. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS. Biol. 2005; 3(11): 339.
PMid:16216086 PMCid:PMC1255740
5. Libert F, Cochaux P, Beckman G, et al. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum. Mol. Genet. 1998; 7(3):399-406.
6. Lucotte G, Mercier G. Distribution of the CCR5 Gene 32-bp Deletion in Europe. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 1998; 19(2):174-177.
7. Kofiadi IA, Rebrikov DV, Trofimov DY. Raspredelenie allelej genov CCR5, CCR2 i SDF1, associirovannyh s ustojchivost’ju k VICh-infekcii, v Rossijskih populjacijah [The distribution of alleles CCR5, CCR2 and SDF1, associated with resistance to HIV infection, in Russian populations]. Doklady akademii nauk – Reports of Academy of Sciences, 2007; 415(6):842-845.
8. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol. 1998; 25(8):1462-1465.
9. Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003; 61(2):238-240.
10. Voropaeva EN, Skvortsov NV, Voevoda MI, Tarnowski RV. Klinicheskoe znachenie delecii gena CCR5 u bol’nyh nehodzhkinskimi zlokachestvennymi limfomami [The clinical significance of the deletion of the CCR5 gene in patients with non-Hodgkin's lymphoma]. Bjulleten’ SO RAMN – Bulletin SB RAMS, 2001; 31(2):26-30.
11. Guyader M, Emerman M, Sonigo P. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987; 326:662-669.
12. McDougal JS, Maddon PJ, Dalgleish AG. The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold. Spring Harb. Symp. Quant. Biol. 1986; 51:703-711.
13. Sattentau QJ, Moore JP. The role of CD4 in HIV binding and entry. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1993; 342(1299):59-66.
14. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272(5270):1955-1958.
15. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85(7):1135-1148.
16. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996; 381(6584):661 – 666.
17. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the betachemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996; 85(7):1149-1158.
18. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381:667-673.
19. Hutter G, Nowak D, Mossner M. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. N. Engl. J. Med. 2009; 360:692-698.
20. Allers K, Hütter G, Hofmann J. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2011; 117(10):2791-2799.
21. Burke BP, Boyd MP, Impey H, et al. CCR5 as a Natural and Modulated Target for Inhibition of HIV. Viruses. 2013; 6(1):54-68.
PMid:24381033 PMCid:PMC3917431
22. Hutter G, Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS. 2011; 25:273-274.
23. Bray RA, Hurley CK, Kamani NR, et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol. Blood Marrow Transplant. 2008; 14:45-53.
24. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583.
25. Petz LD, Redei I, Bryson Y, et al. Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections. Biol. Blood Marrow Transplant. 2013; 19(3):393-397.
PMid:23089564 PMCid:PMC4651173
26. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118(2):282-288.
PMid:21527516 PMCid:PMC3138683
27. Spellman SR, Eapen M, Logan BR, et al. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood. 2012; 120(2):259-265.
PMid:22596257 PMCid:PMC3398760
28. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 1989; 321(17):1174-1178.
29. Gluckman E, Ruggeri A, Volt F. Milestones in umbilical cord blood transplantation. Br. J. Haematol. 2011; 154(4):441-447.
30. Chen YH, Xu LP, Liu DH, et al. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis. Chin. Med. J. (Engl). 2013; 126(13):2499-2503.
31. Smith AR, Baker KS, Defor TE, et al. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol. Blood Marrow Transplant. 2009; 15(9):1086-1093.
32. Tomblyn MB, Arora M. Baker KS, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J. Clin. Oncol. 2009; 27(22):3634-3641.
PMid:19581540 PMCid:PMC2720079
33. Gutman JA, Leisenring W, Appelbaum FR., et al. Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol. Blood Marrow Transplant. 2009; 15(9):1122-1129.
PMid:19660726 PMCid:PMC2723722
34. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. The Lancet Oncology. 2010; 11(7):653-660.
35. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010; 16(22):4693-4699.
PMid:20686119 PMCid:PMC2996124
36. Zhang MJ, Davies SM, Camitta BM, et al. Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia. Biol. Blood Marrow Transplant. 2012; 8(8):1204-1210.
PMid:22406037 PMCid:PMC3890239
37. Rubinstein P, Dobrila L, Rosenfield RE., et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc. Natl. Acad. Sci. USA. 1995; 92(22):10119-10122.
38. McKenna DH, et al. Umbilical cord blood. Core Principles in cellular therapy. AABB, Bethesda. 2008; 3:47-72.
39. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011; 118(24):6438-6445.
PMid:21976674 PMCid:PMC3236125
40. Magro E, Regidor C, Cabrera R, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica. 2006; 91(5):640-648.
41. Sebrango A, Vicu-a I, de Laiglesia A. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes. Best Pract. Res. Clin. Haematol. 2010; 23(2):259-274.
42. Stanevsky A, Shimoni A, Yerushalmi R, et al. Double umbilical cord blood transplant: more than a cell dose? Leuk. Lymphoma. 2010; 51(6):975-982.
43. Scaradavou A, Brunstein CG, Eapen M. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013; 121(5):752-758.
PMid:23223509 PMCid:PMC3563363
44. Gonzalez G, Park SS. Chen DW, et al. Identification and frequency of CCR5Delta32/Delta32 HIV-resistant cord blood units from Houston area hospitals. HIV Med. 2011; 12(8): 481-486.
PMid:21375684 PMCid:PMC4021858

Pirozhkov IA, Smolyaninov AB, Chechetkin AV, Ivolgin DA. Scientific-organizational aspects for developing an inventory of the donors of umbilical cord blood with ccr5 delta32/delta32 genotype for hiv infection treatment. Cell and Organ Transplantology. 2014; 2(1): doi: 10.22494/COT.V2I1.37


Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.